Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Translational Stroke Research
Published in: Translational Stroke Research 6/2013

01-12-2013 | Editorial

Fast Neuroprotection (Fast-NPRX) for Acute Ischemic Stroke Victims: the Time for Treatment Is Now

Author: Paul A. Lapchak

Published in: Translational Stroke Research | Issue 6/2013

Login to get access

Excerpt

Since the inception of Translational Stroke Research, numerous significant scientific breakthroughs have been published as peer-reviewed contributions, and some have lead the way for significant advances in the stroke field, opening up new ways to think about stroke therapy research and development [1‐5], animal models [6‐9], mechanisms of injury and the ischemic cascade [3, 10‐14], and clinical trials [1, 15‐18]. Many of the scientific advances are being directly applied to discover therapeutic approaches, but there remain some gaps in the systematic approaches being used to treat stroke patients. The best use or way of using neuroprotective agents and the clinical trial to adequately test them is somewhat of an unfinished puzzle. We have yet to put the pieces together to assemble a coherent picture and have success with a neuroprotectant.
“Learning is not attained by chance, it must be sought for with ardor and attended to with diligence.”―Abigail Adams (1744–1818).
…
Literature
1.
Lapchak PA, Zhang JH, Noble-Haeusslein LJ. RIGOR guidelines: escalating STAIR and STEPS for effective translational research. Transl Stroke Res. 2013;4(3):279–85.PubMedCrossRef
2.
Lapchak PA, Zhang JH. Resolving the negative data publication dilemma in translational stroke research. Transl Stroke Res. 2011;2(1):1–6.PubMedCrossRef
3.
Lapchak PA. Emerging therapies: pleiotropic multi-target drugs to treat stroke victims. Transl Stroke Res. 2011;2(2):129–35.PubMedCrossRef
4.
Fagan SC, Lapchak PA, Liebeskind DS, Ishrat T, Ergul A. Recommendations for preclinical research in hemorrhagic transformation. Transl Stroke Res. 2013;4(3):322–7.PubMedCrossRef
5.
Bahjat FR, Gesuete R, Stenzel-Poore MP. Steps to translate preconditioning from basic research to the clinic. Transl Stroke Res. 2013;4(1):89–103.PubMedCrossRef
6.
Winters A, Taylor JC, Ren M, Ma R, Liu R, Yang SH. Transient focal cerebral ischemia induces long-term cerebral vasculature dysfunction in a rodent experimental stroke model. Transl Stroke Res. 2012;3(2):279–85.PubMedCrossRef
7.
Turner RJ, Jickling GC, Sharp FR. Are underlying assumptions of current animal models of human stroke correct: from STAIRs to high hurdles? Transl Stroke Res. 2011;2(2):138–43.PubMedCrossRef
8.
Tajiri N, Dailey T, Metcalf C, Mosley YI, Lau T, Staples M, et al. In vivo animal stroke models: a rationale for rodent and non-human primate models. Transl Stroke Res. 2013;4(3):308–21.PubMedCrossRef
9.
Lapchak PA. Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. Transl Stroke Res. 2010;1(2):96–107.PubMedCrossRef
10.
Ahmad M, Graham SH. Inflammation after stroke: mechanisms and therapeutic approaches. Transl Stroke Res. 2010;1(2):74–84.PubMedCrossRef
11.
Vemuganti R. The microRNAs and stroke: no need to be coded to be counted. Transl Stroke Res. 2010;1(3):158–60.PubMedCrossRef
12.
Elgebaly MM, Ogbi S, Li W, Mezzetti EM, Prakash R, Johnson MH, et al. Neurovascular injury in acute hyperglycemia and diabetes: a comparative analysis in experimental stroke. Transl Stroke Res. 2011;2(3):391–8.PubMedCrossRef
13.
Davis CM, Fairbanks SL, Alkayed NJ. Mechanism of the sex difference in endothelial dysfunction after stroke. Transl Stroke Res. 2013;4(4):381–9.PubMedCrossRef
14.
Herson PS, Palmateer J, Hurn PD. Biological sex and mechanisms of ischemic brain injury. Transl Stroke Res. 2013;4(1):413–9.PubMedCrossRef
15.
Fagan SC, Cronic LE, Hess DC. Minocycline development for acute ischemic stroke. Transl Stroke Res. 2011;2(2):202–8.PubMedCrossRef
16.
Fujii M, Yan J, Rolland WB, Soejima Y, Caner B, Zhang JH. Early brain injury, an evolving frontier in subarachnoid hemorrhage research. Transl Stroke Res. 2013;4(4):432–46.PubMedCrossRef
17.
Huang B, Khatibi NH, Tong L, Yan P, Xie P, Zhang JH. Magnesium sulfate treatment improves outcome in patients with subarachnoid hemorrhage: a meta-analysis study. Transl Stroke Res. 2010;1(2):108–12.PubMedCrossRef
18.
Switzer JA, Sikora A, Ergul A, Waller JL, Hess DC, Fagan SC. Minocycline prevents IL-6 increase after acute ischemic stroke. Transl Stroke Res. 2012;3(3):363–8.PubMedCrossRef
19.
Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, et al. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354(6):588–600.PubMedCrossRef
20.
Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357(6):562–71.PubMedCrossRef
21.
Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009;40(12):e647–56.PubMedCrossRef
22.
Saver JL. Targeting the brain: neuroprotection and neurorestoration in ischemic stroke. Pharmacotherapy. 2010;30(7 Pt 2):62S–9.PubMedCrossRef
23.
Dafer RM, Biller J. Desmoteplase in the treatment of acute ischemic stroke. Expert Rev Neurother. 2007;7(4):333–7.PubMedCrossRef
24.
Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, et al. Dose escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006;37(5):1227–31.PubMedCrossRef
25.
Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36(1):66–73.PubMedCrossRef
26.
Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009;8(2):141–50.PubMedCrossRef
27.
28.
Zivin JA, Albers GW, Bornstein N, Chippendale T, Dahlof B, Devlin T, et al. Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke. 2009;40(4):1359–64.PubMedCrossRef
29.
30.
NINDS. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581–7.CrossRef
31.
Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366(12):1099–107.PubMedCrossRef
32.
Parsons MW, Miteff F, Bateman GA, Spratt N, Loiselle A, Attia J, et al. Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology. 2009;72(10):915–21.PubMedCrossRef
33.
Haley Jr EC, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010;41(4):707–11.PubMedCrossRef
34.
Lapchak PA, Araujo DM, Zivin JA. Comparison of tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol. 2004;185(1):154–9.PubMedCrossRef
35.
O’Collins VE, Donnan GA, Howells DW. History of animal models of stroke. Int J Stroke. 2011;6(1):77–8.PubMedCrossRef
36.
Casals JB, Pieri NC, Feitosa ML, Ercolin AC, Roballo KC, Barreto RS, et al. The use of animal models for stroke research: a review. Comp Med. 2011;61(4):305–13.PubMed
37.
O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59(3):467–77.PubMedCrossRef
38.
Liebeskind DS, Kasner SE. Neuroprotection for ischaemic stroke: an unattainable goal? CNS Drugs. 2001;15(3):165–74.PubMedCrossRef
39.
Minnerup J, Sutherland BA, Buchan AM, Kleinschnitz C. Neuroprotection for stroke: current status and future perspectives. Int J Mol Sci. 2012;13(9):11753–72.PubMedCrossRef
40.
Feuerstein GZ, Zaleska MM, Krams M, Wang X, Day M, Rutkowski JL, et al. Missing steps in the STAIR case: a translational medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab. 2008;28(1):217–9.PubMedCrossRef
41.
42.
Meloni BP, Cross JL, Brookes LM, Clark VW, Campbell K, Knuckey NW. FAST-Mag protocol with or without mild hypothermia (35 degrees C) does not improve outcome after permanent MCAO in rats. Magnes Res. 2013;26(2):67–73. Off Org Int Soc Dev Res Magnes.PubMed
43.
Gorelick PB, Ruland S. IMAGES and FAST-MAG: magnesium for acute ischaemic stroke. Lancet Neurol. 2004;3(6):330.PubMedCrossRef
44.
Saver JL, Kidwell C, Eckstein M, Starkman S, Investigators F-MPT. Prehospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial. Stroke. 2004;35(5):e106–8.PubMedCrossRef
45.
Saver JL, Smith EE, Fonarow GC, Reeves MJ, Zhao X, Olson DM, et al. The “golden hour” and acute brain ischemia: presenting features and lytic therapy in >30,000 patients arriving within 60 minutes of stroke onset. Stroke. 2010;41(7):1431–9.PubMedCrossRef
46.
Sanossian N, Starkman S, Eckstein M, Stratton S, Pratt F, Conwit R, et al. Intercontinental elicitation of informed consent for enrollment in stroke research. Cerebrovasc Dis. 2010;30(3):323–4.PubMedCrossRef
47.
Sanossian N, Starkman S, Liebeskind DS, Ali LK, Restrepo L, Hamilton S, et al. Simultaneous ring voice-over-Internet phone system enables rapid physician elicitation of explicit informed consent in prehospital stroke treatment trials. Cerebrovasc Dis. 2009;28(6):539–44.PubMedCrossRef
48.
Schlachetzki F, Herzberg M, Holscher T, Ertl M, Zimmermann M, Ittner KP, et al. Transcranial ultrasound from diagnosis to early stroke treatment: part 2: prehospital neurosonography in patients with acute stroke: the Regensburg stroke mobile project. Cerebrovasc Dis. 2012;33(3):262–71.PubMedCrossRef
49.
Holscher T, Schlachetzki F, Zimmermann M, Jakob W, Ittner KP, Haslberger J, et al. Transcranial ultrasound from diagnosis to early stroke treatment. 1. Feasibility of prehospital cerebrovascular assessment. Cerebrovasc Dis. 2008;26(6):659–63.PubMedCrossRef
50.
Holscher T, Dunford JV, Schlachetzki F, Boy S, Hemmen T, Meyer BC, et al. Prehospital stroke diagnosis and treatment in ambulances and helicopters—a concept paper. Am J Emerg Med. 2013;31(4):743–7.PubMedCrossRef
51.
Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010;67(2):181–98.PubMedCrossRef
52.
Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–29.PubMedCrossRef
53.
Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke. 2009;40(7):2438–41.PubMedCrossRef
54.
Fang MC, Cutler DM, Rosen AB. Trends in thrombolytic use for ischemic stroke in the United States. J Hosp Med. 2010;5(7):406–9.PubMedCrossRef
55.
Reeves MJ, Arora S, Broderick JP, Frankel M, Heinrich JP, Hickenbottom S, et al. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke. 2005;36(6):1232–40.PubMedCrossRef
56.
Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL, Messe S, et al. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at get with the guidelines—stroke hospitals. Circ Cardiovasc Qual Outcome. 2013;6(5):543–9.
57.
Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL. A Model of Cost-effectiveness of Tissue Plasminogen Activator in Patient Subgroups 3 to 4.5 Hours After Onset of Acute Ischemic Stroke. Ann Emerg Med. 2012.
58.
Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695–703.PubMedCrossRef
59.
Desai JA, Smith EE. Prenotification and other factors involved in rapid tPA administration. Curr Atheroscler Rep. 2013;15(7):337.PubMedCrossRef
60.
Olson DM, Constable M, Britz GW, Lin CB, Zimmer LO, Schwamm LH, et al. A qualitative assessment of practices associated with shorter door-to-needle time for thrombolytic therapy in acute ischemic stroke. J Neurosci Nurs. 2011;43(6):329–36.PubMedCrossRef
61.
Fonarow GC, Smith EE, Saver JL, Reeves MJ, Hernandez AF, Peterson ED, et al. Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association’s Target: stroke initiative. Stroke. 2011;42(10):2983–9.PubMedCrossRef
62.
Fonarow GC, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Grau-Sepulveda MV, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011;123(7):750–8.PubMedCrossRef
63.
Wardlaw JM, Koumellis P, Liu M. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. Cochrane Database Syst Rev. 2013;5, CD000514.PubMed
64.
Bluhmki E, Chamorro A, Davalos A, Machnig T, Sauce C, Wahlgren N, et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009;8(12):1095–102.PubMedCrossRef
65.
Ricci S, Cenciarelli S, Mazzoli T. Italian guidelines on thrombolysis indications in ischaemic stroke have been revised after IST 3 trial and Cochrane review: PROS. Intern Emerg Med. 2013. doi:10.​1007/​s11739-013-0987-x.
66.
Costantino G, Podda GM, Bonzi M, Sbrojavacca R, Gruppo di Autoformazione Metodologica. Italian guidelines on thrombolysis indications in ischemic stroke have been revised after IST-3 trial and Cochrane revision: cons. Intern Emerg Med. 2013. doi:10.​1007/​s11739-013-0986-y.
67.
Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013;309(23):2480–8.PubMedCrossRef
68.
Lapchak PA. Recommendations and practices to optimize stroke therapy: developing effective translational research programs. Stroke. 2013;44(3):841–3.PubMedCrossRef
69.
Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490(7419):187–91.PubMedCrossRef
70.
STAIR. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30(12):2752–8.CrossRef
71.
Saver JL, Albers GW, Dunn B, Johnston KC, Fisher M. Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Stroke. 2009;40(7):2594–600.PubMedCrossRef
72.
McKim Jr JM. Building a tiered approach to in vitro predictive toxicity screening: a focus on assays with in vivo relevance. Comb Chem High Throughput Screen. 2010;13(2):188–206.PubMedCrossRef
73.
Lapchak PA, KcKim JM. CeeTox™ analysis of CNB-001 a novel curcumin-based neurotrophic/neuroprotective lead compound to treat stroke: comparison with NXY-059 and Radicut. Transl Stroke Res. 2011;2(1):51–9.PubMedCrossRef
74.
75.
76.
Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics–2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18–209.PubMedCrossRef
77.
78.
Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480–6.PubMedCrossRef
79.
Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(7):2064–89.PubMedCrossRef
80.
81.
82.
Lampl Y, Zivin JA, Fisher M, Lew R, Welin L, Dahlof B, et al. Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1). Stroke. 2007;38(6):1843–9.PubMedCrossRef
83.
Leonardo CC, Robbins S, Dore S. Translating basic science research to clinical application: models and strategies for intracerebral hemorrhage. Front Neurol. 2012;3:85.PubMedCrossRef
84.
Cook DJ, Tymianski M. Nonhuman primate models of stroke for translational neuroprotection research. Neurotherapeutics. 2012;9(2):371–9.PubMedCrossRef
85.
Cook DJ, Teves L, Tymianski M. A translational paradigm for the preclinical evaluation of the stroke neuroprotectant Tat-NR2B9c in gyrencephalic nonhuman primates. Sci Transl Med. 2012;4(154):154ra33.CrossRef
86.
Woodruff TM, Thundyil J, Tang SC, Sobey CG, Taylor SM, Arumugam TV. Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Mol Neurodegener. 2011;6(1):11.PubMedCrossRef
87.
Bordet R, Ouk T, Onteniente B, Charriaut-Marlangue C, Heurteaux C. Cerebral ischaemia: tomorrow’s therapeutic tracks. Med Sci (Paris). 2009;25(10):847–54.CrossRef
88.
Lo EH, Rosenberg GA. The neurovascular unit in health and disease: introduction. Stroke. 2009;40(3 Suppl):S2–3.PubMedCrossRef
89.
Ferguson KN, Kidwell CS, Starkman S, Saver JL. Hyperacute treatment initiation in neuroprotective agent stroke trials. J Stroke Cerebrovasc Dis. 2004;13(3):109–12.PubMedCrossRef
Metadata
Title
Fast Neuroprotection (Fast-NPRX) for Acute Ischemic Stroke Victims: the Time for Treatment Is Now
Author
Paul A. Lapchak
Publication date
01-12-2013
Publisher
Springer US
Published in
Translational Stroke Research / Issue 6/2013
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI
https://doi.org/10.1007/s12975-013-0303-0

Other articles of this Issue 6/2013

Translational Stroke Research 6/2013 Go to the issue

Original Article

Augmentation of Normal and Glutamate-Impaired Neuronal Respiratory Capacity by Exogenous Alternative Biofuels

Original Article

ER Stress and Effects of DHA as an ER Stress Inhibitor

Editorial

The Editorial for this Special Issue

Original Article

Lysosomal Membrane Permeabilization as a Key Player in Brain Ischemic Cell Death: a “Lysosomocentric” Hypothesis for Ischemic Brain Damage

Review Article

Protein Misfolding, Aggregation, and Autophagy After Brain Ischemia

Original Article

HuR Function and Translational State Analysis Following Global Brain Ischemia and Reperfusion